Document is current

Any future updates will be listed below

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

Crossref DOI link: https://doi.org/10.1186/s12885-026-16297-4

Published Online: 2026-06-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark